ImmunoGen Inc (IMGN.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|64||2009||Independent Chairman of the Board|
|52||2016||President, Chief Executive Officer, Director|
|61||2013||Chief Financial Officer, Executive Vice President|
|61||2014||Chief Human Resource Officer, Vice President|
|58||2015||Executive Vice President - Research, Chief Scientific Officer|
- BRIEF-Biotest says Immunogen not to exercise late stage co-development option for US-market with Biotest's antibody-drug conjugate
- BRIEF-Immunogen files for mixed shelf of up to $200 mln – SEC filing
- BRIEF-Immunogen sees FY 2017 revenue $70 mln to $75 mln
- BRIEF-ImmunoGen announces first patient dosed in phase 3 study of mirvetuximab soravtansine in platinum-resistant ovarian cancer
- BRIEF-Immunogen announces departure of Sandra Poole